Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Employees

609

Sector

Biotechnology & Medical Research

Calendar

2024-12-10 - Global CVCT Forum

More about the company

Quotes

Date	Price	Change	Volume
24-12-09	23.27 $	-1.44%	1,101,946
24-12-06	23.61 $	+5.87%	1,366,198
24-12-05	22.30 $	-3.50%	2,045,392
24-12-04	23.11 $	-11.35%	2,654,846
24-12-03	26.07 $	-1.03%	1,656,104

Delayed Quote Nasdaq, December 09, 2024 at 04:00 pm EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart ARROWHEAD-PHARMACEUTICALS

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

23.27USD

Average target price

47.15USD

Spread / Average Target

+102.64%

Consensus

Profit revisions

estimates-change-chart ARROWHEAD-PHARMACEUTICALS

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart ARROWHEAD-PHARMACEUTICALS

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-09 pm EST			5-day change	1st Jan Change
23.27 ^USD	-1.44%		-10.60%	-23.95%

Dec. 03	HC Wainwright Raises Price Target on Arrowhead Pharmaceuticals to $80 From $60, Keeps Buy Rating	MT
Dec. 03	Arrowhead Pharmaceuticals Files Request to Initiate Phase 1/2a Trial of Obesity Treatment	MT

Capitalization	2.94B 2.78B 2.58B 2.3B 4.16B 249B 4.56B 32.05B 11.84B 102B 11.03B 10.79B 444B	P/E ratio 2025 *	-7.8x	P/E ratio 2026 *	-7.84x
Enterprise value	2.64B 2.5B 2.32B 2.07B 3.74B 224B 4.1B 28.8B 10.64B 91.9B 9.91B 9.7B 399B	EV / Sales 2025 *	10.5x	EV / Sales 2026 *	10.4x
Free-Float	-	Yield 2025 *	-	Yield 2026 *	-

HC Wainwright Raises Price Target on Arrowhead Pharmaceuticals to $80 From $60, Keeps Buy Rating	Dec. 03	MT
Arrowhead Pharmaceuticals Files Request to Initiate Phase 1/2a Trial of Obesity Treatment	Dec. 03	MT
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2A Study of ARO-ALK7 for the Treatment of Obesity	Dec. 03	CI
Wall Street soars as global indices stumble in the shadows	Nov. 27
Analyst recommendations: Nvidia, Workday, Doordash, Nutanix, T-Mobile...	Nov. 27
Arrowhead Pharmaceuticals Fiscal Q4 Loss Widens, Revenue Declines	Nov. 26	MT
Arrowhead Pharmaceuticals, Inc., 2024 Earnings Call, Nov 26, 2024	Nov. 26
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024	Nov. 26	CI
Sector Update: Health Care Stocks Higher Late Afternoon	Nov. 26	MT
Sector Update: Health Care Stocks Advance Tuesday Afternoon	Nov. 26	MT
Sector Update: Health Care	Nov. 26	MT
Top Midday Gainers	Nov. 26	MT
Arrowhead Pharma, Sarepta Therapeutics Sign Licensing, Partnership Deal for Clinical, Preclinical Programs	Nov. 26	MT

HC Wainwright Raises Price Target on Arrowhead Pharmaceuticals to $80 From $60, Keeps Buy Rating	Dec. 03	MT
Analyst recommendations: Nvidia, Workday, Doordash, Nutanix, T-Mobile...	Nov. 27
Analyst recommendations: Estee Lauder, Sentinelone, Snowflake, Wolfspeed, Admiral...	Aug. 22
Analyst recommendations: Epam Systems, Five9, T-Mobile, Lyft, Under Armour...	Aug. 09
Analyst recommendations: CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap...	Jul. 23

Arrowhead Pharmaceuticals, Inc. Stock

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Valuation: Arrowhead Pharmaceuticals, Inc.

Chart: Arrowhead Pharmaceuticals, Inc.

Latest news: Arrowhead Pharmaceuticals, Inc.

Last Transcript: Arrowhead Pharmaceuticals, Inc.

Analysts' recommendations: Arrowhead Pharmaceuticals, Inc.

Press Releases: Arrowhead Pharmaceuticals, Inc.

News in other languages: Arrowhead Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Arrowhead Pharmaceuticals, Inc.

ETFs: Arrowhead Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity	Dec. 03	BU
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences	Dec. 02	BU
Arrowhead Pharmaceuticals : Reports 2024 Fiscal Year End Results Form 8 K	Nov. 26	PU
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results	Nov. 26	BU
Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs	Nov. 26	BU

RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Estee Lauder, Sentinelone, Snowflake, Wolfspeed, Admiral...	Aug. 22
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Epam Systems, Five9, T-Mobile, Lyft, Under Armour...	Aug. 09
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU. : CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap...	Jul. 23
GSK : licence pour un traitement expérimental de l'hépatite B	23-10-31
Dow Jones Industrial Average : Les valeurs à suivre à Wall Street	18-10-04

1 day	-1.44%
1 week	-10.60%
Current month	-10.60%
1 month	+6.30%
3 months	+4.73%
6 months	-2.68%
Current year	-23.95%

Director	Title	Age	Since
Christopher Anzalone CEO	Chief Executive Officer	54	2007-11-30
Kenneth Myszkowski DFI	Director of Finance/CFO	57	2008-12-31
Bruce Given COO	Chief Operating Officer	69	2011-10-25

Manager	Title	Age	Since
Christopher Anzalone BRD	Director/Board Member	54	2007-11-30
Mauro Ferrari BRD	Director/Board Member	64	2010-08-18
Douglass Given CHM	Chairman	71	2013-01-07

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.40%	0 M€	0.00%	-
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.35%	0 M€	0.00%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ARROWHEAD PHARMACEUTICALS, INC.	-1.44%	-10.60%	-2.84%	-68.54%	2.94B
VERTEX PHARMACEUTICALS INCORPORATED	+2.57%	+1.25%	+35.36%	+129.41%	119B
REGENERON PHARMACEUTICALS, INC.	+1.29%	+5.04%	-6.21%	+20.48%	83.7B
ARGENX SE	-0.95%	-0.20%	+38.02%	+123.02%	37.69B
BIONTECH SE	-0.74%	+2.05%	+16.81%	-58.61%	29.18B
BEIGENE, LTD.	+0.97%	-3.43%	+18.64%	-34.10%	21.85B
WUXI APPTEC CO., LTD.	+6.81%	+17.63%	-22.39%	-57.72%	21.71B
GENMAB A/S	+0.81%	+2.33%	-30.66%	-40.60%	14.53B
SUMMIT THERAPEUTICS INC.	+0.65%	+1.08%	+752.05%	+264.45%	13.67B
INSMED INCORPORATED	-3.49%	-3.18%	+160.26%	+155.42%	13.49B
Average	+0.65%	+0.73%	+95.91%	+43.32%	35.78B
Weighted average by Cap.	+1.38%	+1.26%	+48.98%	+64.18%

	2025 *	2026 *
Net sales	251M 237M 220M 197M 355M 21.25B 389M 2.73B 1.01B 8.72B 940M 920M 37.89B	248M 235M 218M 194M 351M 21.02B 385M 2.7B 999M 8.63B 930M 910M 37.48B
Net income	-502M -476M -441M -394M -712M -42.59B -780M -5.48B -2.02B -17.48B -1.89B -1.84B -75.94B	-405M -384M -356M -318M -574M -34.34B -629M -4.42B -1.63B -14.09B -1.52B -1.49B -61.23B
Net Debt	-298M -282M -262M -234M -422M -25.26B -462M -3.25B -1.2B -10.37B -1.12B -1.09B -45.04B	-352M -333M -309M -276M -498M -29.82B -546M -3.83B -1.42B -12.24B -1.32B -1.29B -53.16B